GlassScriptPhysician profile
Waleed F Nemer
NPI 1235121211
$6,463.26
in general payments reported to CMS, 2019-2025
33 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,254 · 2020: $862 · 2021: $1,109 · 2022: $1,296 · 2023: $812 · 2024: $621 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $914.10 | 2019-2025 | |
| Amarin Pharma, INC. | $819.49 | 2019-2023 | |
| Glaxosmithkline, LLC. | $738.58 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $662.21 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $442.42 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $407.60 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $378.72 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $353.26 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $319.37 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Esperion Therapeutics, INC. | $199.84 | 2020-2024 | Nexletol |
| Exact Sciences Corporation | $197.08 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $132.89 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $88.47 | 2019-2022 | |
| Lilly USA, LLC | $87.72 | 2022-2024 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.79 | 2021-2023 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $73.50 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $64.36 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $59.69 | 2024-2025 | Voquezna |
| Abbott Laboratories | $58.87 | 2022-2023 | Freestyle Libre 3 |
| Nevro Corp. | $56.83 | 2021-2022 | |
| Allergan, INC. | $50.44 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.62 | 2022 | |
| Renalytix Ai, INC. | $39.18 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Corcept Therapeutics | $31.42 | 2024 | Korlym |
| Janssen Pharmaceuticals, INC | $28.34 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.63 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $21.77 | 2021 | |
| Arbor Pharmaceuticals, INC. | $21.75 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.80 | 2024 | Gvoke Hypopen |
| Biocryst US Sales Co., LLC | $16.62 | 2025 | Orladeyo |
| Ironwood Pharmaceuticals, INC | $16.56 | 2020 | |
| Horizon Therapeutics Plc | $15.91 | 2023 | Krystexxa |
| Sumitomo Pharma America, INC. | $2.43 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waleed Nemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.